• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗复杂高危和有指征血运重建后的全因死亡率的临床结局和预测因素。

Clinical Outcomes and Predictors of All-Cause Mortality After Complex High-Risk and Indicated Revascularization Using Percutaneous Coronary Intervention.

机构信息

Department of Cardiology, Yokkaichi Municipal Hospital.

Department of Cardiology, Aichi Medical University.

出版信息

Int Heart J. 2023;64(4):570-576. doi: 10.1536/ihj.22-710.

DOI:10.1536/ihj.22-710
PMID:37518336
Abstract

The concept of complex and high-risk indicated procedures using percutaneous coronary intervention (CHIP-PCI) has recently been defined. However, few studies have investigated the prognosis of patients after CHIP-PCI. We enrolled 322 consecutive patients who underwent CHIP-PCI. CHIP-PCI was defined as a procedure satisfying at least one criterion each for both patient and procedure characteristics, as follows: patient characteristics [age ≥ 75 years old, low left ventricular ejection fraction (LVEF), diabetes mellitus, acute coronary syndrome, previous coronary artery bypass surgery, peripheral arterial disease, severe chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and severe valvular disease] and procedure characteristics [unprotected left main disease, degenerated saphenous or radial artery grafts, severely calcified lesions, last patent conduit, chronic total occlusions, multivessel disease, and use of mechanical circulatory support]. On Kaplan-Meier analysis, 1-, 2-, and 3-year survival rates following CHIP-PCI was 93.8%, 89.2%, and 85.4%, respectively. Moreover, on Cox multivariate hazard analysis, age (≥ 75 years old) (hazard ratio: 4.01, 95% confidence interval: 1.92-8.38, P < 0.01), COPD (hazard ratio: 2.95, 95% confidence interval: 1.38-6.32, P < 0.01), low LVEF (hazard ratio: 3.35, 95% confidence interval: 1.55-7.22, P < 0.01), severe CKD (hazard ratio: 3.02, 95% confidence interval: 1.44-6.36, P < 0.01), and use of mechanical circulatory support (hazard ratio: 5.97, 95% confidence interval: 2.72-13.10, P < 0.01) remained significant predictors of mortality. In conclusion, we revealed the clinical outcomes after CHIP-PCI. The presence of advanced age, COPD, low LVEF, severe CKD, and mechanical circulatory support use might lead to worse clinical outcomes.

摘要

最近已经定义了使用经皮冠状动脉介入治疗(PCI)的复杂和高危指示性程序(CHIP-PCI)的概念。然而,很少有研究调查 CHIP-PCI 后患者的预后。我们纳入了 322 例连续接受 CHIP-PCI 的患者。CHIP-PCI 的定义是满足以下患者和手术特征的至少一个标准的程序:患者特征[年龄≥75 岁,左心室射血分数(LVEF)低,糖尿病,急性冠状动脉综合征,既往冠状动脉旁路移植术,外周动脉疾病,严重慢性肾脏病(CKD),慢性阻塞性肺疾病(COPD)和严重的瓣膜疾病]和手术特征[无保护的左主干疾病,退化的大隐静脉或桡动脉移植物,严重钙化病变,最后一个通畅的导管,慢性完全闭塞,多血管疾病和使用机械循环支持]。在 Kaplan-Meier 分析中,CHIP-PCI 后的 1、2 和 3 年生存率分别为 93.8%、89.2%和 85.4%。此外,在 Cox 多变量风险分析中,年龄(≥75 岁)(风险比:4.01,95%置信区间:1.92-8.38,P<0.01),COPD(风险比:2.95,95%置信区间:1.38-6.32,P<0.01),LVEF 低(风险比:3.35,95%置信区间:1.55-7.22,P<0.01),严重 CKD(风险比:3.02,95%置信区间:1.44-6.36,P<0.01)和使用机械循环支持(风险比:5.97,95%置信区间:2.72-13.10,P<0.01)仍然是死亡的重要预测因素。总之,我们揭示了 CHIP-PCI 后的临床结果。高龄、COPD、LVEF 低、严重 CKD 和机械循环支持的使用可能导致更差的临床结果。

相似文献

1
Clinical Outcomes and Predictors of All-Cause Mortality After Complex High-Risk and Indicated Revascularization Using Percutaneous Coronary Intervention.经皮冠状动脉介入治疗复杂高危和有指征血运重建后的全因死亡率的临床结局和预测因素。
Int Heart J. 2023;64(4):570-576. doi: 10.1536/ihj.22-710.
2
Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions≤50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2).比较左心室射血分数≤50%与>50%的患者行冠状动脉旁路移植术与经皮冠状动脉介入治疗的 5 年预后(来自 CREDO-Kyoto PCI/CABG 注册研究队列-2)。
Am J Cardiol. 2014 Oct 1;114(7):988-96. doi: 10.1016/j.amjcard.2014.07.007. Epub 2014 Jul 16.
3
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.冠状动脉血运重建术后卒率比较:外科手术与经皮冠状动脉介入治疗。
J Am Coll Cardiol. 2018 Jul 24;72(4):386-398. doi: 10.1016/j.jacc.2018.04.071.
4
Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左心室射血分数严重降低患者的长期预后
JAMA Cardiol. 2020 Jun 1;5(6):631-641. doi: 10.1001/jamacardio.2020.0239.
5
Impact of chronic obstructive pulmonary disease on prognosis after percutaneous coronary intervention and bypass surgery for left main coronary artery disease: an analysis from the EXCEL trial.慢性阻塞性肺疾病对左主干冠状动脉疾病经皮冠状动脉介入治疗和旁路手术后预后的影响:来自 EXCEL 试验的分析。
Eur J Cardiothorac Surg. 2019 Jun 1;55(6):1144-1151. doi: 10.1093/ejcts/ezy438.
6
Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial.左主干病变行经皮冠状动脉介入治疗和冠状动脉旁路移植术后大围术期心肌梗死对死亡率的影响:来自 EXCEL 试验的分析。
Eur Heart J. 2019 Jun 21;40(24):1930-1941. doi: 10.1093/eurheartj/ehz113.
7
[Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].[经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗无保护左主干冠状动脉分叉病变的长期预后比较]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jan 25;45(1):19-25. doi: 10.3760/cma.j.issn.0253-3758.2017.01.005.
8
Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study.慢性阻塞性肺疾病对复杂冠状动脉疾病经皮冠状动脉介入治疗和旁路手术后 10 年死亡率的影响:来自 SYNTAX 扩展生存研究的见解。
Clin Res Cardiol. 2021 Jul;110(7):1083-1095. doi: 10.1007/s00392-021-01833-y. Epub 2021 Mar 12.
9
Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.经皮冠状动脉介入治疗开口/中段病变与无保护左主干冠状动脉分叉病变的长期临床结局:DELTA 注册研究(左主干冠状动脉疾病药物洗脱支架):一项多中心注册研究,评估经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干的疗效。
JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.
10
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with reduced ejection fraction.射血分数降低的患者行经皮冠状动脉介入治疗与冠状动脉旁路移植术的比较。
J Thorac Cardiovasc Surg. 2021 Mar;161(3):1022-1031.e5. doi: 10.1016/j.jtcvs.2020.06.159. Epub 2020 Sep 16.

引用本文的文献

1
High-Risk Factors of In-Hospital Death Following Complex High-risk and Indicated Patients After Percutaneous Coronary Intervention Supported by Extracorporeal Membrane Oxygenation.体外膜肺氧合支持下经皮冠状动脉介入治疗后复杂高危及特定患者院内死亡的高危因素
Rev Cardiovasc Med. 2025 May 26;26(5):27126. doi: 10.31083/RCM27126. eCollection 2025 May.
2
Application of Drug-Coated Balloons in Complex High Risk and Indicated Percutaneous Coronary Interventions.药物涂层球囊在复杂高危及特定经皮冠状动脉介入治疗中的应用
Catheter Cardiovasc Interv. 2025 Feb;105(2):494-516. doi: 10.1002/ccd.31316. Epub 2024 Dec 11.